Clinical Trials Directory

Trials / Completed

CompletedNCT02020330

Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day

An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
150 (actual)
Sponsor
University of Oxford · Academic / Other
Sex
All
Age
6 Years
Healthy volunteers
Not accepted

Summary

This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms. The standard regimen is twice daily for three days with a delay of at least eight hours between the first and second doses. A single of primaquine will be given to all patients on the first day of treatment for gametocytocidal activity. The initial treatment will be given under supervision, all other subsequent doses will be given to the patient to the taken at home. Patients will be followed up for nine visits over forty two days.

Detailed description

* The study will be conducted in 6 village health centres in the Mon and Kayin states * The patient or parent/guardian (in case of minor or under aged) must personally sign and date the latest approved version of the informed consent form before any study specific procedures are performed * A case record form will be completed for each patient documenting symptoms prior to clinic attendance, concomitant illness, drug history. Height, weight, vital signs and physical examination findings will be recorded. * At enrolment (D0) all patients will have the following samples taken: * Repeat parasite count (thick and thin films). Treatment should be started without waiting for the result. * Filter paper blood blots (3 dots on Whatman 3MM filter paper approx 180-300 µL blood) for parasite genotyping (MSP1, MSP2, GLURP in case of recurrence during follow-up) * Haemoglobin * Laboratory procedures * Slide microscopy: Thick and thin blood films stained with Giemsa will be read and counts expressed as the number of parasites per 500 white blood cells * Molecular studies: The samples will be used to detect asexual parasites (blood smear, sensitive PCR), parasite population structure (Sequenom genotyping and sequencing), gametocytes (microscopy). The samples will be stored in a cool box and kept maximum 5 days in the field and will be transported to the local laboratory for processing. Plasma and buffy coat will be separated, frozen and stored. The frozen packed red cells will be transported to the molecular laboratory at MORU, Bangkok, Thailand, for sample processing (DNA extraction, quantitative PCRs).

Conditions

Interventions

TypeNameDescription
DRUGArtemether-lumefantrine 3 daysOne tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
DRUGArtemether-lumefantrine 5 daysOne tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.

Timeline

Start date
2013-11-25
Primary completion
2015-02-04
Completion
2015-03-25
First posted
2013-12-24
Last updated
2018-09-20

Locations

1 site across 1 country: Burma

Source: ClinicalTrials.gov record NCT02020330. Inclusion in this directory is not an endorsement.